Currently, it is estimated that up to 69% of advanced NSCLC patients have druggable mutations in numerous genes, including EGFR, anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), Kirsten rat sarcoma virus (KRAS), V-raf murine sarcoma oncogene homolog B1 (BRAF), MET, human epidermal growth factor receptor (HER2), and other genes [10]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.